Temozolomide (one week on/one week off) versus radiotherapy in primary therapy of anaplastic astrocytomas and glioblastomas in elderly patients

Randomized phase III study Methvsalem/NOA-08

Phase: III

Recruited patients: 412 out of 412

The NOA-08 trial is a prospective, randomized study to determine whether temozolomide chemotherapy is equivalent to radiation therapy in patients with malignant glioma over the age of 65. The study will also determine quality of life and prognostic molecular parameters and resistance factors (MGMT).


MGMT testing-the challenges for biomarker-based glioma treatment. Wick W, Weller M, van den Bent M, Sanson M, Weiler M, von Deimling A, Plass C, Hegi M, Platten M, Reifenberger G. Nat Rev Neurol. 2014;10: 372 – 385.

Malignant astrocytoms of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective. Wiestler B, Claus R, Hartlieb SA, Schliesser MG, Weiss EK, Hielscher T, Platten M, Dittmann LM, Meisner C, Felsberg J, Happold C, Simon M, Nikkhah G, Papsdorf K, Steinbach JP, Sabel M, Grimm C, Weichenhan D, Tews B, Reifenberger G, Capper D, Müller W, Plass C, Weller M, Wick W; Neuro-oncology Working Group (NOA) of the German Cancer Society. Neuro Oncol. 2013;15: 1017 – 1026.

Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, Nikkhah G, Papsdorf K, Steinbach JP, Sabel M, Combs SE, Vesper J, Braun C, Meixensberger J, Ketter R, Mayer-Steinacker R, Reifenberger G, Weller M; NOA-08 Study Group of Neuro-oncology Working Group (NOA) of German Cancer Society. Lancel Oncol. 2012;13: 707 – 715